Baidu
map

重磅!上海明确国家组织药品集中采购和使用试点有关工作

2019-02-20 高雅静 上海阳光医药采购网

此前,国务院办公厅已经发布关于印发国家组织药品集中采购和使用试点方案的通知,选择北京、天津、上海、重庆和沈阳、大连、厦门、广州、深圳、成都、西安11个城市开展试点工作。2月19日,上海阳光医药采购网正式发布《关于本市做好国家组织药品集中采购和使用试点有关工作的通知》(以下简称“通知”),同时通知还给出了国家组织药品集中采购试点品种通用名及使用同品种“价高药”个人提高的自负比例。优先采购和使用中选药

此前,国务院办公厅已经发布关于印发国家组织药品集中采购和使用试点方案的通知,选择北京、天津、上海、重庆和沈阳、大连、厦门、广州、深圳、成都、西安11个城市开展试点工作。

2月19日,上海阳光医药采购网正式发布《关于本市做好国家组织药品集中采购和使用试点有关工作的通知》(以下简称“通知”),同时通知还给出了国家组织药品集中采购试点品种通用名及使用同品种“价高药”个人提高的自负比例。

优先采购和使用中选药品

1.上海市所有非营利性医疗机构和医保定点医疗机构不得以费用总控、“药占比”、医院基本用药品种数量为由影响中选药品的供应与合理使用。原先未采购中选企业品种,应当及时召开药事委员会,简化和加快采购流程。

2.医疗机构应当从中选企业指定的药品经营或配送企业采购中选品种,并按规定实行零差率销售,严禁任何形式的“二次议价”行为,使用量原则上不低于上一年度同期水平。

3.未中选药品药品数量不得超过中选品种。医疗机构采购质量和疗效有保证,且价格适宜的未中选药品视作符合“一品两规”要求。

4.医疗机构要充分发挥临床药师作用,加强医疗机构处方审核和处方点评,进一步强化合理用药考核。严格落实按通用名开具处方的要求,确保在同等条件下优先选择中选药品;与中选品种具有相同或相当活性成分(特别是化学结构类似),以及同等治疗效果(包括复方制剂),临床可替代的同类药品,应当在合理用药的基础上,优先使用中选药品。对使用中选药品可能导致患者用药调整的情况,医疗机构要强化临床风险评估、预案制定和物资准备,加强医师和药师宣传培训,并对患者做好解释说明。

未选中“价高药”要降价,提高患者自负比例

1.对通用名属于《上海市基本医疗保险、工伤保险和生育保险药品目录(2017年版)》,但价格高于中选价格的同通用名未中选药品(以下简称“价高药”),按照“价格适宜”原则在梯度降价或限价后挂网公开议价采购。

2.对“价高药”适当提高个人自负比例(老红军、离休人员和一至六级革命伤残军人除外)。

3.本市城镇职工基本医疗保险和城乡居民基本医疗保险参保人员使用“价高药”的,药品自负比例提高10%(基本药物和医保甲类支付的药品)或20%(其他药品)。

4.实行个人定额自负的抗癌药,参照上述药品适当上调定额自负标准。

5.参加本市社区医疗互助帮困计划人员参照执行。住院患者使用“价高药”的,统一按出院时新的自负比例结算。

6.参保人员使用“价高药”的,医疗机构在医疗费用收据的项目明细中应予标注,以供识别。

最后,通知还提到自此次试点结果执行之日起实施,其中城乡居民基本医疗保险参保人员使用“价高药”需提高的药品自负比例执行时间由本市医保部门另行通知。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1694313, encodeId=18301694313a2, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Sat Mar 23 11:11:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641694, encodeId=782116416941c, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Tue Mar 19 18:11:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460117, encodeId=6431146011e98, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532826, encodeId=020c1532826ac, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549449, encodeId=2b0b154944945, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1694313, encodeId=18301694313a2, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Sat Mar 23 11:11:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641694, encodeId=782116416941c, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Tue Mar 19 18:11:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460117, encodeId=6431146011e98, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532826, encodeId=020c1532826ac, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549449, encodeId=2b0b154944945, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1694313, encodeId=18301694313a2, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Sat Mar 23 11:11:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641694, encodeId=782116416941c, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Tue Mar 19 18:11:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460117, encodeId=6431146011e98, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532826, encodeId=020c1532826ac, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549449, encodeId=2b0b154944945, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1694313, encodeId=18301694313a2, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Sat Mar 23 11:11:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641694, encodeId=782116416941c, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Tue Mar 19 18:11:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460117, encodeId=6431146011e98, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532826, encodeId=020c1532826ac, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549449, encodeId=2b0b154944945, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1694313, encodeId=18301694313a2, content=<a href='/topic/show?id=12a48e51263' target=_blank style='color:#2F92EE;'>#药品集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87512, encryptionId=12a48e51263, topicName=药品集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d77629597748, createdName=cathymary, createdTime=Sat Mar 23 11:11:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641694, encodeId=782116416941c, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Tue Mar 19 18:11:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460117, encodeId=6431146011e98, content=<a href='/topic/show?id=cb9d98e23ee' target=_blank style='color:#2F92EE;'>#集中采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98723, encryptionId=cb9d98e23ee, topicName=集中采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1406243727, createdName=liuxiaona, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532826, encodeId=020c1532826ac, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549449, encodeId=2b0b154944945, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Feb 22 03:11:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
    2019-02-22 xxxx1054

相关资讯

这一药品 全面停产、停售

中国医药作出回应:上海新兴医药已全面停产、停售,对上市公司影响较小该产品,全面停产、停售前日(2月10日),中国医药发布公告,对其下属控股子公司上海新兴静注人免疫球蛋白事件作出说明。公告显示,在得知消息后, 上海新兴全面停产 ,全面排查问题批次产品的原料来源、生产及质量控制全流程等各重要环节中可能存在的问题。此外, 上海新兴通知相关单位全面停止销售、使用、封存并召回问题批次产品,同时对问题批次产品

2018年度FDA对中国企业发出进口警报数据分析

美国FDA是全球最严苛的药政监管机构之一,一直致力于全面保障美国本土消费者的健康和安全。随着药品生产、流通和使用的日益全球化,中国作为原药料和制剂出口大国,而美国作为原料药和仿制药制剂的主要进口国,因此对美国本土以外的原料药和仿制药药品生产企业受到的监管越来越严苛;另一方面,全球化药品生产供应链带来不断的挑战,中国国内的制剂企业也在不断创新和发展,持续加大国际化认证和注册布局和投入,试图努力进军美

上海加强药品采购使用管理:严禁返点返利,不得进行二次议价

新华社上海2月12日消息,记者从上海市卫生健康委获悉,上海近日专门下发通知,严禁医疗机构要求企业返点、返利行为;医疗机构按照合同购销药品,不得进行“二次议价”。根据上海市卫生健康委下发的《关于进一步加强药品、医疗器械采购使用管理有关工作的通知》,上海严格对药品及采购发票进行审核,防止标外采购、违价采购或从非正规渠道采购药品。此外,对通过带量采购、谈判、定点生产等方式形成的采购价格,医院不得另行组织

多地药品带量采购细则陆续出台,力促患者买到降价药

个城市开展国家组织药品集中采购和使用试点工作。近期,包括天津、大连、沈阳等城市药品带量采购细则陆续出台,各地针对推动药品提质降价有何举措?面对药价“腰斩”,药企又将如何应对?一系列问题成为关注焦点。资料图:民众在医院排队取药。中新社记者 张添福 摄3月下旬起 患者将陆续用上试点采购药品根据国办印发的《方案》,此次共有北京、天津、上海、重庆、沈阳、大连、厦门、广州、深圳、成都、西安11个城市,开展试

国家组织药品集中采购和使用试点进入落地实施阶段

据经济之声《天下财经》报道,过去这一年,新成立的国家医保局通过一系列改革,为广大患者送来不少红包,例如,跨省异地就医定点医疗机构数量超过15000家,17种抗癌药纳入医保,为患者减轻药费负担超过75%。国家医保局:政府部门并不直接参与药品采购《国务院办公厅关于印发国家组织药品集中采购和使用试点方案的通知》近日发布,这标志着上海、北京等11个城市试点的药品集中采购和使用进入落实阶段,市场和社会对这项

国务院常务会议:对首批21个罕见病药品减按3%征收增值税

2月11日,国务院总理李克强主持召开国务院常务会议,听取2018年全国两会建议提案办理工作汇报,推进提升政府施政水平;要求狠抓今年脱贫攻坚任务落实,为打赢脱贫攻坚战奠定坚实基础;部署加强癌症早诊早治和用药保障的措施,决定对罕见病药品给予增值税优惠;决定支持商业银行多渠道补充资本金,增强金融服务实体经济和防风险能力。会议指出,加强癌症、罕见病等重大疾病防治,事关亿万群众福祉。一要加快完善癌症诊疗体系

Baidu
map
Baidu
map
Baidu
map